Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Donohue

Pulmonary Disease Chapel Hill, NC Medical Doctor

NPI 1740353556 CMS profile 305485

101 Manning Dr, Chapel Hill, NC 27599

Open in the dashboard

General payments

$270,764

255 records reported · program years 2019–2025

Research payments

$42,600

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Donohue of Chapel Hill, NC is reported in the CMS Open Payments database as having received $270,764 across 255 general payments and $42,600 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $13,654 10
2025 Research $800 1
2024 General $9,263 6
2024 Research $41,000 1
2023 General $14,929 10
2022 General $37,261 19
2021 General $26,127 18
2020 General $33,390 30
2019 General $136,140 162
2019 Research $800 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Donohue
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to James Donohue were reported at $13,654. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year James Donohue Pulmonary Disease median Middle half National median
2019 $136,140 $377 $109–$1,340 $163
2020 $33,390 $230 $56–$907 $114
2021 $26,127 $269 $68–$1,072 $132
2022 $37,261 $390 $100–$1,457 $149
2023 $14,929 $419 $114–$1,659 $160
2024 $9,263 $476 $123–$1,818 $164
2025 $13,654 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Mylan Specialty L.P. $60,717 88 payments
  2. GlaxoSmithKline, LLC. $60,192 67 payments
  3. Insmed, Inc. $31,727 19 payments
  4. Grifols USA, LLC $25,763 30 payments
  5. AstraZeneca UK Limited $20,614 15 payments
  6. Mylan Inc. $10,780 6 payments
  7. Ucb SA $9,800 4 payments
  8. Sanofi US Services Inc. $9,217 3 payments
  9. Chiesi USA, Inc. $8,975 4 payments
  10. PneumRx, Inc $7,636 2 payments
  11. Other $25,344 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $138,604 81 payments
  2. Consulting Fee $111,662 63 payments
  3. Travel and Lodging $15,989 52 payments
  4. Food and Beverage $3,909 58 payments
  5. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $600 1 payment
Products named General payments · program years 2019–2025
  1. Yupelri $63,397 89 payments
  2. TRELEGY ELLIPTA $33,389 25 payments
  3. Prolastin-C Liquid $20,739 22 payments
  4. NUCALA $13,180 11 payments
  5. ANORO $12,119 25 payments
  6. FASENRA $10,500 6 payments
  7. BREZTRI $8,947 7 payments
  8. PNEUMRX COILS $7,636 2 payments
  9. Prolastin-C $5,844 9 payments
  10. SPIRIVA $4,930 3 payments
  11. Other $19,812 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Boehringer Ingelheim International GmbH $41,800 2 payments
  2. Chiesi USA, Inc. $800 1 payment

Records

258 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record